They indeed highlighted its efficacy in mitigating cardiomyocyte hypertrophy (dose 12.5 μg/mL) and reducing DGKζ and glycerophospholipid metabolizing enzymes group VI phospholipase A2 mRNA and protein expression induced by the isoproterenol treatment, but the mechanism of action has not been yet completely understood and further studied are needed, even if this molecule is commercially available as DGKζ inhibitor [212] and has been employed for the experimental treatment of head and neck cancer [219]. Here, DGKZ is linked to head and neck cancer.